CX Precision Medicine is Changing Expectations for People with Dementia

Written By Kathleen Otto

Danguole Altman

More than 6 million Americans are living with Alzheimer’s Disease, and even more with Dementia and Parkinson’s. CX Precision Medicine’s CEO, Danguole Altman, is focused on tackling this big problem for an aging population. Based on Dr. Sid O’Bryant’s revolutionary research at HSC, CX Precision Medicine is bringing this important diagnostic technology to help people all over the world.

Through a clinical diagnostic, CX Precision Medicine is conducting screening tests to detect Alzheimer’s and other neurodegenerative diseases based on blood biomarkers, AI and machine learning. CX aims to “Change eXpectations” around how doctors diagnose Alzheimer’s and dementia.

Kathleen Otto
Previous

Meet 10 Women Who Are Leading The Synthetic Biology Revolution
Next

Research Bridge Partners Collaborates with Lyda Hill Philanthropies to Support UTSW Scientist with $4M Investment